Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-331-3p
Specific or universal ncRNAs
Specific ncRNAs
Class
MicroRNA
Biomarker
None
Biomarker application
Upstream regulatory factors
Not available
Downstream target
ST7L
Cancer name
Pancreatic Cancer
Cancer site
qRT-PCR,Western blot
Treatment type
Chemotherapy
Drug
Gemcitabine
Impact of wild-type ncRNA on chemotherapy resistance
Up
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
our data demonstrate that miR-331-3p contributes to drug resistance by activating Wnt/Ī²-catenin signaling via ST7L in pancreatic cancer cells
Tissue resource
patients with prostate cancer who had received chemotherapy and had not received chemotherapy plasma samples
human prostate cancer cell lines PANC1
human prostate cancer cell lines MIAPaCa2
prostate cancer drug-resistant cell lines PANC1/Gem
prostate cancer drug-resistant cell lines MIAPaCa2/Gem
Experiment
None
Institute
the Tongren Hospital of Wuhan University and Renmin Hospital of Wuhan University
Cell Bank of Type Culture Collection of Chinese Academy of Sciences
the Central Laboratory of Renmin Hospital of Wuhan University
Country
China
China
China
Continent
Asia
Asia
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.